ORKA-003

ORKA-003 is a monoclonal antibody developed by Oruka Therapeutics and now under the active development of Paragon Therapeutics. The specific target and mechanism of action for ORKA-003 have not been publicly disclosed, as the company has withheld further details due to competitive considerations. It is described as a new molecular entity in early research and preclinical development, with no clinical trials or approved indications reported as of June 2025[1][2][9]. Based on Oruka’s pipeline focus, which includes advanced biologics targeting validated cytokine pathways for inflammatory diseases such as psoriasis and psoriatic arthritis, it is possible that ORKA-003 may be directed at similar immunological targets (e.g., IL-23p19 or related cytokines), but this has not been confirmed in public disclosures[3][4]. The route of administration is parenteral (likely intravenous or subcutaneous), consistent with other monoclonal antibodies from this developer[2].

Other names

ORKA 003ORKA003ORKA-003